Unconfigured Ad

Collapse

Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc

Forums Topics Posts Last Post
No forums found.
  •  
  • Time
  • Answered
  • Show
  • New Topics
Clear All
new posts
There are no conversations in this channel.
 
  • Time
  • Show
Clear All
new posts
Please log in to your account to view your subscribed posts.
  •  
  • Time
  • Answered
  • Show
  • Sort By
  • Order
Clear All
new posts
Topics Statistics Last Post
Started by laura, 05-09-2011, 04:42 AM
35 responses
107,959 views
0 reactions
Last Post laura
by laura
 
Started by sci_guy, 01-23-2008, 11:19 PM
236 responses
688,038 views
1 reaction
Last Post ECO
by ECO
 
Started by dadada4ever, 06-05-2013, 03:18 AM
3 responses
2,978 views
0 reactions
Last Post dadada4ever  
Started by gremlinsplash, 06-10-2013, 06:03 PM
0 responses
1,139 views
0 reactions
Last Post gremlinsplash  
Started by [email protected], 06-10-2013, 04:15 PM
0 responses
1,649 views
0 reactions
Last Post thaarapillai@gmail.com  
Started by mariovandeivans, 06-10-2013, 12:50 PM
0 responses
1,009 views
0 reactions
Last Post mariovandeivans  
Started by crkessen, 06-05-2013, 01:33 PM
2 responses
1,884 views
0 reactions
Last Post crkessen  
Started by twid, 06-10-2013, 10:11 AM
2 responses
2,478 views
0 reactions
Last Post twid
by twid
 
Started by staylor, 01-26-2010, 07:46 AM
31 responses
22,284 views
0 reactions
Last Post JonB
by JonB
 
Started by marco12345, 06-10-2013, 06:31 AM
0 responses
2,499 views
0 reactions
Last Post marco12345  
Started by DIV, 06-10-2013, 05:00 AM
0 responses
1,815 views
0 reactions
Last Post DIV
by DIV
 
Started by xulong, 06-01-2013, 04:40 PM
15 responses
2,517 views
0 reactions
Last Post xulong
by xulong
 
No topics found.
  • Time
Clear All
No photos found.
  • Time
Clear All

Webinars

Collapse

Recent Articles

Collapse

  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    Today, 10:25 AM
  • SEQadmin2
    How Immunogenomics Decodes Immunity’s Genetic Blueprint
    by SEQadmin2




    The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.

    This convergence of genetics, immunology, and computation...
    09-01-2026, 05:41 AM
  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 09-25-2026, 09:06 AM
0 responses
27 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 09-23-2026, 11:05 AM
0 responses
24 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 09-18-2026, 11:37 AM
1 response
45 views
0 reactions
Last Post pekgio
by pekgio
 
Working...